Laverdiere Michel, Labbé Annie-Claude, Restieri Christiane, Rotstein Coleman, Heyland Daren, Madger Sheldon, Stewart Thomas
University of Montreal, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada H1T 2M4.
J Crit Care. 2007 Sep;22(3):245-50. doi: 10.1016/j.jcrc.2006.10.038. Epub 2007 Jan 31.
The objective of this study was to determine the speciation and susceptibility patterns of Candida species recovered from Canadian intensive care units (ICUs) during a 1-day point-prevalence study on fungal colonization/infection in Canadian ICUs.
Blood, urine, respiratory tract, rectal, and wound fungal cultures were performed for 357 patients present at any time during a single-day 24-hour period in 35 Canadian ICUs. Comparative in vitro activities of amphotericin B, fluconazole, itraconazole, voriconazole, posaconazole, micafungin, anidulafungin, and aminocandin were determined.
Four hundred fifteen yeasts (409 Candida species and 6 non-Candida yeasts) were recovered. Almost 50% of the patients were found to have positive respiratory tract or rectal cultures. Candida albicans accounted for 72% of the Candida species isolated, followed by Candida glabrata (16%), Candida tropicalis (5%), Candida parapsilosis (3%), Candida krusei (2%), and other Candida species or nonspeciated isolates (2%). Minimum inhibitory concentrations (milligrams per liter) at which 90% of the strains were inhibited were 0.06 for micafungin as well as anidulafungin, 0.12 for voriconazole, 0.25 for itraconazole, posaconazole, as well as aminocandin, 1 for amphotericin B, and 4 for fluconazole. Only 4% of the isolates were resistant to fluconazole and/or itraconazole.
Candida albicans is the predominant species colonizing Canadian ICU patients. Overall, the triazoles, both older and new compounds, and the echinocandins have excellent in vitro antifungal activities against Candida species recovered from Canadian ICUs patients.
本研究的目的是在加拿大重症监护病房(ICU)进行的为期1天的真菌定植/感染现患率研究中,确定从加拿大ICU分离出的念珠菌属的种类和药敏模式。
对加拿大35个ICU在单日24小时内任何时间在场的357例患者进行血液、尿液、呼吸道、直肠和伤口真菌培养。测定了两性霉素B、氟康唑、伊曲康唑、伏立康唑、泊沙康唑、米卡芬净、阿尼芬净和氨基环醇的体外比较活性。
共分离出415株酵母菌(409株念珠菌属和6株非念珠菌属酵母菌)。近50%的患者呼吸道或直肠培养结果为阳性。白色念珠菌占分离出的念珠菌属的72%,其次是光滑念珠菌(16%)、热带念珠菌(5%)、近平滑念珠菌(3%)、克柔念珠菌(2%)以及其他念珠菌属或未鉴定菌株(2%)。90%菌株被抑制时的最低抑菌浓度(毫克/升),米卡芬净和阿尼芬净为0.06,伏立康唑为0.12,伊曲康唑、泊沙康唑和氨基环醇为0.25,两性霉素B为1,氟康唑为4。仅4%的分离株对氟康唑和/或伊曲康唑耐药。
白色念珠菌是定植于加拿大ICU患者的主要菌种。总体而言,新旧三唑类药物以及棘白菌素类药物对从加拿大ICU患者中分离出的念珠菌属具有优异的体外抗真菌活性。